In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness and safety of ublituximab (TG-1101) and TGR-1202 with or without bendamustine (Treanda), as well as TGR-1202 alone in treating patients with relapsed or refractory non-Hodgkin’s lymphoma. The primary outcome will be measured by the overall response. The details...
Read More
In a nutshell This phase 1 clinical trial will test the safety of ABL001 alone and with either nilotinib (Tasigna), imatinib (Gleevec), or dasatinib (Sprycel) in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic Leukemia (Ph+ALL). The primary outcome will be measured by side effects. The details...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...
Read More
In a nutshell This trial looked at therapy that activates the immune system to kill cancerous tumors in patients with extensive stage small cell lung cancer (ES-CLC). The authors concluded pembrolizumab (Keytruda) is tolerable and a promising treatment for patients with heavily treated ES-SCLC. Some background Extensive-stage small cell lung...
Read More
In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate. The details Axicabtagene ciloleucel is a chimeric antigen...
Read More
In a nutshell This review outlined the opinions of the American Society of Clinical Oncology for the treatment of hormone therapy resistant men with prostate cancer. Some background Advanced prostate cancer is cancer that has spread outside the prostate gland into surrounding organs. In some cases, cancer can become hormone-resistant. This is when...
Read More
In a nutshell The authors looked at the effect of age on outcomes for Hodgkin lymphoma patients who have undergone autologous stem cell transplantation. The authors concluded older patients tend to have a worse outcome than younger patients, and have a higher risk of developing a secondary cancer. Some background Hodgkin lymphoma (HL) is...
Read More
In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...
Read More
In a nutshell This paper reviewed advances in treatment options for relapsed and refractory chronic lymphocytic leukemia. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the blood and blood forming cells. Despite a good response to initial therapy, most patients relapse and require further treatment. Some patients may stop...
Read More
